Skip to content

A randomized controlled clinical study on the treatment of acute myocardial infarction combined with acute upper gastrointestinal bleeding with Huangtu decoction based on the theory of "spleen governs blood" and "distant blood" in the Synopsis of Jin Gui

A randomized controlled clinical study on the treatment of acute myocardial infarction combined with acute upper gastrointestinal bleeding with Huangtu decoction based on the theory of "spleen governs blood" and "distant blood" in the Synopsis of Jin Gui

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000189
Enrollment
Unknown
Registered
2025-01-26
Start date
2024-02-01
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction

Interventions

treatment group:Oral Huangtu decoction combined with conventional treatment
control group:Oral placebo combined with conventional treatment

Sponsors

Guang'anmen Hospital Chinese Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1) Western medicine diagnosis meets the diagnostic criteria for acute myocardial infarction and acute upper gastrointestinal bleeding; 2) Patients were included in the risk stratification for acute upper gastrointestinal bleeding which included moderate risk low risk and extremely low risk; 3) Diagnosed with Yang deficiency and bleeding syndrome independently by two deputy chief physicians or chief physicians of traditional Chinese medicine; 4) Age = 18 years old; 5) All selected patients are able to complete all treatments in this study and are required to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1) The risk stratification of acute upper gastrointestinal bleeding is extremely high and high-risk patients require emergency rescue or strict fasting and water requirements; 2) Individuals with language communication barriers or other reasons who are unable to cooperate with treatment and follow-up; 3) Pregnant and lactating patients. Any of the above criteria can be excluded.

Design outcomes

Primary

MeasureTime frame
hemostatic time;

Secondary

MeasureTime frame
Glasgow Blatchford bleeding score;Major cardiovascular adverse events;kidney function indicators;liver function indicators;GRACE score;72 hourrebleeding rates;myocardial injury markers;heart rate;Blood pressure;NT-ProBNP;7 days rebleeding rates;transfusion status;TCM syndrome score;blood clotting;hemoglobin;

Countries

China

Contacts

Public ContactXiong Xingjiang

Guang'anmen Hospital Chinese Academy of Traditional Chinese Medicine

5dministration@163.com15801463736

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026